The aim of our study was to discover any relation between infection, including deep infections, after knee total joint arthroplasty in patients who had previous intra-articular hyaluronic acid injections compared to those who had not. We performed a retrospective review of 1776 patients who had osteoarthritis and received hyaluronic acid injections and then a subsample of 415 patients who subsequently underwent total joint arthroplasty: a large primary researchable database from 2002-2008. Surgery was conducted in a university academic network, while the hyaluronic acid injections were delivered in a large primary care arthritis referral center. The 415 patients had at least one year follow-up after total joint arthroplasty. Outcomes included demographics, pre-post total joint arthroplasty Western Ontario McMaster score, and clinical outcomes (knee flexion and extension), as well as adverse events including infection rates. Infections were determined on clinical grounds and confirmed with laboratory investigations. In the injection group there were 18 cases of infected total joint arthroplasty versus 21 in the no-hyaluronic-acid-injection group. However, when the type of hyaluronic acid derivative was considered, more infections with higher versus lower molecular weight (15 vs. 3) were observed. Hence, prior intra-articular hyaluronic acid does not increase the risk of subsequent infection post total joint arthroplasty.
Introduction
Intra-articular injections of hyaluronic acid (HA) derivative agents are utilized currently in the treatment of mild-to-moderate osteoarthritis of the knee [1] [2] [3] [4] and other degenerative joints. [5] [6] [7] [8] While there have been reports on longer-term efficacy, [9] [10] often HA is used as a temporary measure to delay more definitive surgery while producing adequate symptom control. As with any other treatment modalities, complications including infection are associated with its use. [11] [12] [13] This is of particular concern because thorough aseptic technique is variable 14 in settings delivering intra-articular HA. While the HA derivative agent is sterilized and delivered under aseptic conditions, often it is administered in an out-patient setting under variable sterile conditions. Most HA derivatives are administered over three to five consecutive weeks, thereby potentially augmenting the potential risk. [3] [4] [5] Current estimates for infection post total joint arthroplasty (TJA) are between 2.9% (superficial) and 0.8% (deep). 15 However, there are no published studies that have correlated the rate of postoperative infection (bacterial) following total knee arthroplasty with previous exposure to intraarticular HA derivative agents. The aim of this study was to discover any relationship between the two.
Materials and Methods
We performed a retrospective review of the patients in a large primary care researchable database 16 who had received a TJA between 2002 and 2008. We identified those patients who had (HA) or had not received intra-articular HA (no HA) in the two years prior to surgery. All patients identified were compared for demographic characteristics, comorbidity using the Charlson index, 17 knee joint physical examination (flexion/extension), and Western Ontario McMaster score (WOMAC) 18 (pre-and one year post-surgery). We excluded patients who had previous operations on the same knee, including high tibial osteotomy, patellectomy, and cruciate ligament reconstruction, and patients who had malignancy, rheumatoid arthritis, osteonecrosis, or previous intraarticular steroid infiltration. In addition, patients who had documentation of infections in the knee or even suspected infection prior to surgery were excluded. All patients in both HA and no-HA groups were at least a year postsurgery, which included a one-year postoperative follow-up assessment.
All patients for knee arthroplasty were selected critically and had shown that they exhausted conservative therapy. In the preoperative assessment, any focus of sepsis was screened for routinely. The knee replacement surgery was carried out in a laminar flow theater. Patients had a loading dose of antibiotic and further postoperative doses as per protocol. A standard midline incision, followed by a medial parapatellar approach was used to gain access to the joint. All implants were inserted with the use of a tourniquet. Antibiotic AKZ simplex P (Stryker, East Rutherford, NJ) bone cement was used. An intramedullary rod in the femoral cuts, extramedullary guide in the tibial cuts, and a spacer block were made to assume appropriate ligament balance. All patients underwent a standardized rehabilitation program, which consisted of early range of motion and weight-bearing exercises as tolerated. All patients also received prophylactic anticoagulation medication and antibiotics as necessary.
Intra-articular HA was administered as previously described. 19 Briefly, under aseptic conditions and the knee flexed to 90 degrees, a 25-23 gauge 1 1 /2 in needle was inserted into the intra-articular space using a medial approach. Aspiration was conducted at the time to ensure adequate positioning of the needle within the intra-articular space. The contents of the needle were administered using a steady flow, and patients were counseled regarding signs of infection post-administration. Analgesics were utilized as needed. The presence of infection was based on clinical symptoms and signs corroborated with appropriate laboratory indices.
Analysis of variance with repeated measures and the χ 2 -test were used to test for differences between groups at baseline and post-TJA. Analyses were conducted using Sigma Stat (SPSS, Chicago, IL, USA) and Microsoft Excel (Microsoft, Redmond, WA, USA). Changes in WOMAC-VAS were calculated in percentages of improvement from baseline. Significance was established at p<0.05.
Results
The reference population included 1776 patients who had osteoarthritis and received HA. Of these, 415 received TJA between 2002 and 2008; 189 patients had not received HA and 226 had received HA prior to TJA. Two hundred and twenty-eight patients who had TJA were excluded for having previous intra-articular corticosteroid, 34 had previous rheumatoid arthritis, and 28 had previous orthopedic 
Demographic characteristics of the study groups and those excluded are given in Table  1 . There were no significant differences among demographic characteristics or comorbidity (Table 1) , or between groups on physical examination of the knee pre-and postoperative one-year follow-up (Table 2 ). There was a small difference in WOMAC presurgery in the HA versus no-HA groups but this was not significantly different ( Table 2 ). The time from the last HA injection to TJA was 21 ± 5 months (range 7-26 months). There were no significant differences in noninfection adverse events. Superficial and deep infections post-TJA were not significantly different between groups ( 
Discussion
Efficacy of intra-articular HA has been proven to be not only safe but effective. 20 Intraarticular injections are associated with a low incidence of adverse events, including infection. Adverse events are reported to be greater in higher molecular weight HA products. 10, 11 Definitive treatment of severe knee osteoarthritis that has exhausted conventional interventions is TJA. To our knowledge, there is no evidence to date regarding the risk of infection post-TJA in patients who had previously received intra-articular HA. We observed no difference in the rates of infection (mainly superficial) post-TJA in patients who had or had not received previous HA injections. Further, there was no difference among patients who had received a single versus multiple courses of HA therapy prior to TJA. Interestingly, we did observe a significant difference in a number of patients who had infection within the HA injection group. Specifically, patients who had received a higher molecular weight HA product had a higher number of post-TJA infections versus those who had received a lower molecular weight treatment. To our knowledge, this is the first report of post-TJA infection rates in patients who had received HA therapy.
Reasons for more infections among those previously exposed to higher molecular weight HA therapy are beyond the scope of this paper. However, a possible mediator could be the higher number of small HA fragments that are precipitated with higher versus lower molecular weight HA treatment. Specifically, HA is broken down into smaller (i.e. <100x10
6 Da) HA fragments of lower molecular weight. 21 It would be anticipated that higher molecular weight products would produce more smaller HA fragments compared to lower molecular weight HA products. Within some tissues these small molecular weight HA fragments have been reported to activate immunocompetent cells. 22 For example, in skin, low molecular weight HA fragments induce activation of keratinocytes, which produce β-defensin-2 mediated by TLR-2 and TLR-4 activation and involving a C-FOSmediated protein kinase C-dependent signaling pathway. This activation is not accompanied by an inflammatory response and, hence, β-defensin may induce a self-defense mechanism from an infection by micro-organisms similarly to what could occur within the intraarticular space. Certainly more investigation will be needed to explore the findings of our study in terms of differences between higher and lower molecular weight products.
This is a retrospective analysis of a primary care database. The methods utilized may not be similar to those used in all primary care settings involved in providing intra-articular HA treatment. While the population may be representative of the Southwestern Ontario region, generalization beyond this should be considered carefully. Certainly, different practices with intra-articular HA administration and TJA should be considered. However, this is a very large and robust database with inclusion of multiple comorbidities that tracks patients' progress over several years. Specifically, we included patients who had received intra-articular HA several years prior to their TJA.
In summary, prior intra-articular HA did not show an increased rate of infection post-TJA. A small but significantly greater number of patients who received higher molecular weight HA had infection after TJA compared to those who received lower molecular weight HA. Hence, further investigation of this finding is needed. Different sources of HA, methods of sterilization, and manufacturing should be compared among those receiving TJA. Lastly, further validation of our findings should be conducted in other populations apart from TJA patient groups. 
